NCT03502694 (STEP) is a Phase 2 clinical trial of Lumicitabine in Metapneumovirus, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT03502694?

NCT03502694 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT03502694?

Interventions in NCT03502694: Lumicitabine, Placebo.

What condition does NCT03502694 study?

NCT03502694 studies Metapneumovirus.

Is NCT03502694 still recruiting?

NCT03502694 is currently withdrawn. Last updated 15 November 2018.

Last reviewed 2018-11-15 · How we verify

NCT03502694: STEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

Withdrawn Phase 2 Last updated 15 November 2018

What this trial tests

Phase 2 trial testing Lumicitabine in Metapneumovirus. Withdrawn.

Timeline

5 November 2018

Primary endpoint
30 April 2019

28 October 2020

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	5 November 2018
Primary completion	30 April 2019
Estimated completion	28 October 2020
Sites	112 locations across France, Japan, Netherlands, Russia, Malaysia, Ukraine, Sweden, Taiwan

Drugs / interventions tested

Lumicitabine — full drug profile →
Placebo

Conditions studied

Metapneumovirus — all drugs for Metapneumovirus →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Metapneumovirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine in hospitalized adult participants infected with human metapneumovirus (hMPV - a virus closely related to respiratory syncytial virus (RSV) and has been identified as an important cause of acute respiratory infections, affecting all age groups) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal hMPV shedding using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) assay.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.
Hijano DR, Maron G, Hayden RT. · · 2018 · cited 69× · PMID 30619176 · DOI 10.3389/fmicb.2018.03097
Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?
Popescu CM, Ursache AL, Feketea G, Bocsan C, et al · · 2019 · cited 9× · PMID 31684063 · DOI 10.3390/microorganisms7110521

Verify or expand the search:

Other trials of Lumicitabine

Trials testing the same drug.

NCT03468777 — A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral · Phase 1 · terminated
NCT03441529 — A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Ora · Phase 1 · completed
NCT03332459 — A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants · Phase 2 · completed
NCT03333317 — A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Admi · Phase 2 · terminated

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03502694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 15 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03502694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing